Pfizer's RSI of 43.5 suggests the stock is neither oversold nor overbought, sitting comfortably in neutral territory despite a $153.1B market cap. The P/E of 19.25 appears reasonable for a mature pharma name, though it warrants comparison against sector peers like JNJ or MRK. The 2.35% short interest is minimal, indicating limited squeeze potential or bearish conviction. What's notable is that PFE trades below its 52-week high, suggesting the stock has retreated from peaks but hasn't triggered capitulation selling. For a defensive healthcare play, this positioning reflects neither extreme optimism nor pessimism—simply a stock consolidating after its rally, with valuation metrics that don't scream either value or overextension.
Snapshot
Recent headlines
Peers in Pharmaceutical Preparations
Build a thesis around PFE
Type a thesis in plain English. AlgoThesis researches it with real data, cites sources, and hands back a tradeable basket.
Open in AlgoThesis →